Stock Track | Bionano Genomics Plunges 6.44% Pre-market on CMS Preliminary Payment Determination

Stock Track

Sep 15

Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday following an announcement regarding a preliminary payment determination by the Centers for Medicare & Medicaid Services (CMS) for Optical Genome Mapping (OGM).

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS had posted the preliminary payment determination for OGM. While the specific details of the determination were not provided in the initial announcement, the market's negative reaction suggests that investors are concerned about potential implications for the company's revenue prospects.

The sharp pre-market decline indicates that shareholders are reassessing the value of Bionano Genomics in light of this development. As OGM is a key technology for the company, any changes in payment determinations by CMS could significantly impact the adoption and reimbursement of Bionano's products in the healthcare market. Investors will likely be closely monitoring further details and the final determination from CMS to gauge the long-term impact on the company's financial outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1138406132"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1138406132\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1138406132?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138406132","market":"nz","top_or_hot":-1,"title":"Stock Track | Bionano Genomics Plunges 6.44% Pre-market on CMS Preliminary Payment Determination","media":"Stock Track","content":"<p>Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday following an announcement regarding a preliminary payment determination by the Centers for Medicare & Medicaid Services (CMS) for Optical Genome Mapping (OGM).</p>\n\n<p>Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS had posted the preliminary payment determination for OGM. While the specific details of the determination were not provided in the initial announcement, the market's negative reaction suggests that investors are concerned about potential implications for the company's revenue prospects.</p>\n\n<p>The sharp pre-market decline indicates that shareholders are reassessing the value of Bionano Genomics in light of this development. As OGM is a key technology for the company, any changes in payment determinations by CMS could significantly impact the adoption and reimbursement of Bionano's products in the healthcare market. Investors will likely be closely monitoring further details and the final determination from CMS to gauge the long-term impact on the company's financial outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bionano Genomics Plunges 6.44% Pre-market on CMS Preliminary Payment Determination</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics Plunges 6.44% Pre-market on CMS Preliminary Payment Determination\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-15 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday following an announcement regarding a preliminary payment determination by the Centers for Medicare & Medicaid Services (CMS) for Optical Genome Mapping (OGM).</p>\n\n<p>Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS had posted the preliminary payment determination for OGM. While the specific details of the determination were not provided in the initial announcement, the market's negative reaction suggests that investors are concerned about potential implications for the company's revenue prospects.</p>\n\n<p>The sharp pre-market decline indicates that shareholders are reassessing the value of Bionano Genomics in light of this development. As OGM is a key technology for the company, any changes in payment determinations by CMS could significantly impact the adoption and reimbursement of Bionano's products in the healthcare market. Investors will likely be closely monitoring further details and the final determination from CMS to gauge the long-term impact on the company's financial outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"","article_id":"1138406132","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138406132","pubTimestamp":1757939056,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday following an announcement regarding a preliminary payment determination by the Centers for Medicare & Medicaid Services...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"个股追踪|Bionano Genomics盘前暴跌6.44%因CMS初步付款认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1},"content_text":"Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday following an announcement regarding a preliminary payment determination by the Centers for Medicare & Medicaid Services (CMS) for Optical Genome Mapping (OGM).\nBionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS had posted the preliminary payment determination for OGM. While the specific details of the determination were not provided in the initial announcement, the market's negative reaction suggests that investors are concerned about potential implications for the company's revenue prospects.\nThe sharp pre-market decline indicates that shareholders are reassessing the value of Bionano Genomics in light of this development. As OGM is a key technology for the company, any changes in payment determinations by CMS could significantly impact the adoption and reimbursement of Bionano's products in the healthcare market. Investors will likely be closely monitoring further details and the final determination from CMS to gauge the long-term impact on the company's financial outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}